{
    "clinical_study": {
        "@rank": "106060", 
        "arm_group": [
            {
                "arm_group_label": "CSL112 - low dose", 
                "arm_group_type": "Experimental", 
                "description": "CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks."
            }, 
            {
                "arm_group_label": "CSL112 - high dose", 
                "arm_group_type": "Experimental", 
                "description": "CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter randomized, double-blind, placebo-controlled, parallel-group,\n      dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of\n      multiple dose administration of two dose levels of CSL112 compared with placebo in subjects\n      with acute myocardial infarction (AMI)."
        }, 
        "brief_title": "A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women, at least 18 years of age, with evidence of myocardial necrosis in a\n             clinical setting consistent with a type I (spontaneous) acute myocardial infarction\n             (AMI), in the last week.\n\n        Exclusion Criteria:\n\n          -  Ongoing hemodynamic instability\n\n          -  Evidence of hepatobiliary disease\n\n          -  Evidence of chronic kidney disease (CKD) (Stage III, IV, or V), defined as moderate\n             or severe renal impairment or if subject is receiving dialysis\n\n          -  Evidence of unstable renal function\n\n          -  History of acute kidney injury after previous exposure to an intravenous contrast\n             agent.\n\n          -  Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its\n             components\n\n          -  Other severe comorbid condition, concurrent medication, or other issue that renders\n             the subject unsuitable for participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108262", 
            "org_study_id": "CSLCT-HDL-12-77", 
            "secondary_id": "2013-003458-26"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CSL112 - low dose", 
                    "CSL112 - high dose"
                ], 
                "description": "CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.", 
                "intervention_name": "CSL112", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "0.9% weight/volume sodium chloride solution (ie, normal saline)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 6, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.", 
        "overall_contact": {
            "email": "clinicaltrials@cslbehring.com", 
            "last_name": "Clinical Trials Registration Coordinator"
        }, 
        "overall_official": {
            "affiliation": "CSL Behring", 
            "last_name": "Dr. Denise D'Andrea", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A clinically important change in drug-induced liver injury is defined as a change (from baseline) in alanine aminotransferase  (ALT) greater than 3 times the upper limit of normal (ULN) or a change in total bilirubin greater than 2 times ULN, that is confirmed upon repeat measurement.", 
                "measure": "Clinically important change in drug-induced liver injury", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline (before 1st infusion) to Day 29."
            }, 
            {
                "description": "A clinically important change in renal status is defined as a serum creatinine (Cr) increase to \u2265 1.5 x the baseline value that is confirmed upon repeat measurement.", 
                "measure": "Clinically important change in renal status", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline (before 1st infusion) to Day 29."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108262"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "MACE includes: cardiovascular death, MI, ischemic stroke and hospitalization for unstable angina.", 
                "measure": "The time-to-first occurrence of a major adverse cardiovascular event (MACE)", 
                "safety_issue": "No", 
                "time_frame": "From the start of the first infusion up to 112 days after infusion"
            }, 
            {
                "description": "Baseline-corrected plasma apoA-I and PC concentrations", 
                "measure": "Pharmacokinetic profile of apolipoprotein A-I (apoA-I) and phosphatidylcholine (PC)", 
                "safety_issue": "No", 
                "time_frame": "Before and for 7 days after the first and last infusions"
            }, 
            {
                "measure": "Plasma apoA-I and PC Cmax", 
                "safety_issue": "No", 
                "time_frame": "Before and for 7 days after the first and last infusions"
            }, 
            {
                "measure": "Plasma apoA-I and PC Tmax", 
                "safety_issue": "No", 
                "time_frame": "Before and for 7 days after the first and last infusions"
            }, 
            {
                "description": "Baseline corrected plasma apoA-I and PC AUC0-infinity, AUC0 last", 
                "measure": "Plasma apoA-I and PC area under the curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Before and for 7 days after the first and last infusions"
            }, 
            {
                "measure": "Plasma apoA-I and PC t1/2", 
                "safety_issue": "No", 
                "time_frame": "Before and for 7 days after the first and last infusions"
            }, 
            {
                "measure": "Plasma apoA-I and PC Clearance", 
                "safety_issue": "No", 
                "time_frame": "Before and for 7 days after the first and last infusions"
            }, 
            {
                "measure": "Plasma apoA-I and PC Volume of distribution at steady state", 
                "safety_issue": "No", 
                "time_frame": "Before and for 7 days after the first and last infusions"
            }, 
            {
                "description": "The number of subjects with study-drug-related AEs", 
                "measure": "Study drug-related adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From the start of the infusion, up to approximately Day 112"
            }, 
            {
                "description": "The total number of subjects with any AE", 
                "measure": "Overall AEs", 
                "safety_issue": "Yes", 
                "time_frame": "From the start of the infusion, up to approximately Day 112"
            }, 
            {
                "description": "The number of subjects who experience bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria (Mehran et al, 2011)", 
                "measure": "Bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "From the start of the infusion, up to approximately Day 112"
            }, 
            {
                "description": "The number of subjects with serum antibodies to CSL112", 
                "measure": "Immunogenic potential of CSL112", 
                "safety_issue": "Yes", 
                "time_frame": "Before infusion, up to approximately Day 112"
            }, 
            {
                "description": "Assessments (i.e., evidence of seroconversion or infection) will be conducted for hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) 1/2, parvovirus B19", 
                "measure": "Change from baseline in serology", 
                "safety_issue": "Yes", 
                "time_frame": "Before infusion, up to approximately Day 382."
            }, 
            {
                "description": "Assessments (i.e., evidence of seroconversion or infection) will be conducted for HAV, HBV, HCV, HIV 1/2, parvovirus B19", 
                "measure": "Change from baseline in nucleic acid testing assessments", 
                "safety_issue": "Yes", 
                "time_frame": "Before infusion, up to approximately Day 382."
            }
        ], 
        "source": "CSL Behring", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CSL Behring", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}